Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Voluntary Operational Update

Deep Longevity's Strategic U.S. Market Entry in Q1 2026

This announcement is made on a voluntary basis by the board (the "**Board**") of directors (the "**Director(s)**") of Regent Pacific Group Limited (the "**Company**" and collectively with its subsidiaries, the "**Group**") to inform the shareholders of the Company and potential investors of the following update in respect of its operations.

The Company today announced that Deep Longevity, Inc, and its subsidiary (collectively, "**Deep Longevity**"), a global leader in explainable AI-driven aging clocks and longevity science, will launch its planned expansion into the United States ("**U.S.**") in the first quarter of 2026. This move positions Deep Longevity at the centre of the world's largest and fastest-growing wellness market, currently valued at more than US$6.8 trillion.

The U.S. offers unmatched scale and demand for evidence-based longevity solutions. Deep Longevity's clinically validated deep aging clocks – including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge – deliver precise, multi-dimensional biological age assessments that go far beyond chronological age. These tools empower consumers, physicians, employers, and insurers with actionable, personalised insights to extend health-span and slow aging.

To drive rapid adoption, Deep Longevity is building a U.S. based sales organisation with the first two salespersons joining on 1 January 2026. The new team will establish high-impact partnerships with longevity platforms, consumer health apps, diagnostic laboratories, wellness clinics, corporate wellness programs, insurance carriers, employers, and premium health-service providers. The team will initially focus their sales efforts on the southeastern region of the U.S., including the states of Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia and West Virginia.

"Entering the U.S. is the most important milestone in Deep Longevity's journey," said **Deepankar Nayak, CEO of Deep Longevity**. *"Our aging clocks are already trusted by leading clinics and platforms worldwide. With a dedicated American team, we are ready to bring personalised, preventive longevity care to millions of people and capture a meaningful share of this US$6.8 trillion opportunity."*

Deep Longevity's technology is backed by dozens of peer-reviewed publications and multiple granted patents. Its multimodal aging clocks integrate blood biomarkers, epigenetics, psychology, biometrics, and soon facial imaging to provide the most comprehensive picture of biological aging available today.

About Deep Longevity

Deep Longevity, Inc, a wholly-owned subsidiary of the Company, together with its subsidiary develop explainable artificial intelligence systems that track human aging at molecular, cellular, organ and psychological levels. Deep Longevity's patented deep aging clocks power vertical software as a service (SaaS)© solutions for consumers, physicians, and enterprises, delivering personalised recommendations proven to improve health and extend healthy lifespan. For more information, visit www.deeplongevity.com.

Media Contact

Deep Longevity communications email: press@deeplongevity.com

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 1 December 2025

As at the date of this announcement, the Board comprises six Directors**:**

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi